BIO-B - Bio-Rad Laboratories, Inc.

NYSE - NYSE Delayed Price. Currency in USD
311.52
0.00 (0.00%)
At close: 10:07AM EDT
Stock chart is not supported by your current browser
Previous Close311.52
Open311.52
Bid308.44 x 800
Ask312.83 x 1000
Day's Range311.52 - 311.52
52 Week Range220.93 - 324.25
Volume137
Avg. Volume103
Market Cap9.237B
Beta (3Y Monthly)1.13
PE Ratio (TTM)16.39
EPS (TTM)19.00
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Facebook churns out a per-employee profit of $635K per year. How that compares with Apple, Google, Cisco, Oracle, Salesforce and others
    American City Business Journals10 days ago

    Facebook churns out a per-employee profit of $635K per year. How that compares with Apple, Google, Cisco, Oracle, Salesforce and others

    Facebook makes more profit per employee than any other tech company on the Fortune 500: A whopping $634,694 per year. Here's how that compares with other major tech employers like Google, Apple and Cisco.

  • Moody's17 days ago

    Bio-Rad Laboratories, Inc. -- Moody's announces completion of a periodic review of ratings of Bio-Rad Laboratories, Inc.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Bio-Rad Laboratories, Inc. New York, July 01, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Bio-Rad Laboratories, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Business Wire21 days ago

    Moody’s Upgrades Bio-Rad to Baa2, Reflecting Recent Improvement in the Company’s Operating Performance

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that Moody’s Investors Service (“Moody’s”) upgraded the unsecured rating of Bio-Rad Laboratories, Inc. senior unsecured notes to Baa2 from Baa3. The upgrade also reflects the company’s consistently strong credit metrics. In explaining its rationale for the upgraded credit rating, Moody’s noted that Bio-Rad’s Baa2 rating is supported by the company’s conservative capital structure and strong credit metrics.

  • Moody's21 days ago

    Bio-Rad Laboratories, Inc. -- Moody's upgrades Bio-Rad to Baa2, outlook is stable

    Moody's Investors Service ("Moody's") upgraded the unsecured rating of Bio-Rad Laboratories, Inc. ("Bio-Rad") to Baa2 from Baa3. The upgrade reflects the recent improvement in Bio-Rad's operating performance, including solid profit margin expansion, and progress made in its multi-year ERP implementation. The upgrade also reflects the company's consistently strong credit metrics.

  • Here’s What Hedge Funds Think About Bio-Rad Laboratories, Inc. (BIO)
    Insider Monkeylast month

    Here’s What Hedge Funds Think About Bio-Rad Laboratories, Inc. (BIO)

    Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. Trends reversed 180 degrees during the first quarter amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]

  • 9 major Bay Area tech employers pay a typical worker more than $200K per year
    American City Business Journalslast month

    9 major Bay Area tech employers pay a typical worker more than $200K per year

    Large Bay Area tech employers that pay a typical employee more than $200,000 per year include the typical suspects like Google parent Alphabet Inc., Facebook and Netflix. But several companies that are lesser-known outside Silicon Valley also pay top dollar for talent.

  • Markitlast month

    See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.

    Bio Rad Laboratories Inc NYSE:BIOView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BIO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIO. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $298 million over the last one-month into ETFs that hold BIO are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wirelast month

    Bio-Rad to Participate in Goldman Sachs Annual Global Healthcare Conference on June 11

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, at 10:40 AM , at the Terranea Resort, Rancho Palos Verdes, California.

  • Business Wire2 months ago

    Bio-Rad to Participate at Jefferies 2019 Global Healthcare Conference on June 4

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, at 10 AM , in New York, NY.

  • Bio-Rad Laboratories Inc (BIO) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Bio-Rad Laboratories Inc (BIO) Q1 2019 Earnings Call Transcript

    BIO earnings call for the period ending March 31, 2019.

  • Associated Press2 months ago

    Bio-Rad: 1Q Earnings Snapshot

    The Hercules, California-based company said it had net income of $28.74 per share. Earnings, adjusted for one-time gains and costs, came to $1.65 per share. The maker of instruments used in biomedical ...

  • Business Wire2 months ago

    Bio-Rad Reports First Quarter 2019 Financial Results

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2019.

  • Netflix and Google now pay a typical employee more than $200K per year. Here's how that compares to Facebook, Intel, Twitter and other big Bay Area tech employers.
    American City Business Journals2 months ago

    Netflix and Google now pay a typical employee more than $200K per year. Here's how that compares to Facebook, Intel, Twitter and other big Bay Area tech employers.

    Netflix and Google employees are now in Silicon Valley's $200K club. The typical Googler earned $246,804 last year — up 25 percent year-over-year. At Netflix, the median employee made $202,335 last year after getting a 10 percent pay boost over 2017.

  • Business Wire3 months ago

    Bio-Rad to Participate in the Bank of America Merrill Lynch Health Care Conference 2019 in May

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in the Bank of America Merrill Lynch Health Care Conference 2019 on May 14, at 10:40 AM Pacific Time, at the Encore Hotel, Las Vegas, Nevada.

  • Business Wire3 months ago

    Bio-Rad Appoints Andrew Last as Executive Vice President and Chief Operating Officer

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dr. Andrew Last as Executive Vice President and Chief Operating Officer, effective April 22, 2019. “We are pleased to have Andrew join Bio-Rad and believe his strong background in global management and leadership spanning the life science, diagnostics, and pharmaceutical industries coupled with his technical expertise will be an invaluable asset to Bio-Rad,” said Norman Schwartz, Bio-Rad President and CEO. Dr. Last brings over 30 years of global management experience to Bio-Rad.

  • Is Bio-Rad Laboratories, Inc. (BIO) A Good Stock To Buy?
    Insider Monkey3 months ago

    Is Bio-Rad Laboratories, Inc. (BIO) A Good Stock To Buy?

    "Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]

  • Business Wire3 months ago

    Bio-Rad to Report First-Quarter 2019 Financial Results

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2019 on Wednesday, May 8, 2019, following the close of the market. Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets.

  • FireEye joins major Bay Area employers like Facebook, Netflix, Google, Microsoft and Salesforce in paying a typical worker more than $150,000 per year
    American City Business Journals3 months ago

    FireEye joins major Bay Area employers like Facebook, Netflix, Google, Microsoft and Salesforce in paying a typical worker more than $150,000 per year

    A small handful of the Bay Area's largest tech employers, including Facebook, Palo Alto Networks, Splunk and Broadcom, pay their median employee above $200,000 per year.

  • Dow Jones Futures: Zogenix Leads 3 Big Movers On FDA News
    Investor's Business Daily3 months ago

    Dow Jones Futures: Zogenix Leads 3 Big Movers On FDA News

    Stock futures: Zogenix plunged early Tuesday on FDA news, while GW Pharma stock rose and PhaseBio stock soared. Bio-Rad won an FDA approval, but shares were quiet near a buy point.

  • Business Wire3 months ago

    Bio-Rad Receives U.S. FDA Clearance for the IH-500, Expanding Its Offering for the Blood Testing Market

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that it has received 510 clearance from the U.S.

  • Business Wire4 months ago

    Bio-Rad Names Ilan Daskal Executive Vice President and Chief Financial Officer

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Ilan Daskal as Executive Vice President and Chief Financial Officer, effective April 6, 2019. Mr. Daskal comes to Bio-Rad from Lumileds, where he served as Chief Financial Officer. Mr. Daskal holds a Masters in Finance degree from City University of New York and a BB in Accounting from Tel-Aviv College of Business in Israel.

  • Business Wire4 months ago

    Bio-Rad Announces Innovative Test to Aid in the Diagnosis of Lyme Disease with the FDA Clearance of the BioPlex 2200 Lyme Total Assay

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance for its BioPlex 2200 Lyme Total Assay, an innovative multiplex test method to aid in the diagnosis of Lyme disease.

  • GlobeNewswire4 months ago

    Recent Analysis Shows Transocean, Chipotle Mexican Grill, Marathon Oil, Laboratory Corporation of America, Bio-Rad Laboratories, and Graco Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.